Dec. 4 at 3:53 AM
$XBI $PFE $LLY
Looking for a sanity check...
If a Bio company issues their Topline trial/primary P2b endpoint data and then 3 months later add this note to a presentation (no mention to it, no PR, just snuck it into a presentation/publication), is there reason for concern?
"One patient randomized to the placebo group received 1.2mg pemvidutide (drug) but was included in the placebo group"
Thanks in advance.
$ALT $VKTX